Introduction
Pancreatic ductal adenocarcinoma is one of the deadliest human malignancies, with an extremely poor 5-year survival rate (Rahib et al. 2014; Siegel et al. 2015) . Although there has been some improvement in the strategies used to diagnose and treat pancreatic cancer, its prognosis is still poor, due to the difficulty with the early detection, differentiating benign from malignant pancreatic lesions, and its aggressive growth behavior (Chakraborty et al. 2011; Hamada and Shimosegawa 2011; Raimondi et al. 2010 ). There is a clear need to develop new diagnostic and therapeutic methods targeting both primary and metastatic pancreatic ductal adenocarcinoma. Recent advances in pancreatic cancer tumor biology allow for a more complete understanding of the genetic and epigenetic changes in pancreatic ductal adenocarcinoma development, metastasis, and progression Abstract Pancreatic cancer is one of the deadliest human malignancies and lack of effective diagnostic and therapeutic methods. Accumulating evidence suggests that the neurotensin (NT) and neurotensin receptors (NTRs) play key roles in pancreatic adenocarcinoma growth and survival. In this study, we not only evaluate the NTR1 expression in pancreatic cancer patient samples, but also explore the PET and fluorescence imaging of NTR1 expression in pancreatic cancer animal models. The NTR1 expression was evaluated by immunohistochemistry staining in clinical patient tissue samples with pancreatic ductal adenocarcinoma, insulinoma, and pancreatitis. The results showed 79.4% positive rate of NRT1 expression in pancreatic ductal adenocarcinoma, compared with 33.3 and 22.7% in insulinoma and pancreatitis samples, respectively. High NTR1 gene expression was also found in Panc-1 cells and confirmed by cell immunofluorescence. 64 Cu-AmBaSar-NT and IRDye800-NT were synthesized as imaging probes and maintained the majority of NTR1-binding affinity. In vivo imaging demonstrated that 64 Cu-AmBaSar-NT has prominent tumor uptake (3.76 ± 1.45 and 2.29 ± 0.10%ID/g at (Hidalgo 2010; Vincent et al. 2011; Wolfgang et al. 2013; Ying et al. 2016) . Identification of molecular markers that contribute to pancreatic tumorigenesis will provide unprecedented opportunities for the development of molecular imaging technologies for the precise diagnosis and treatment monitoring of pancreatic ductal adenocarcinoma.
Accumulating evidence suggests that neurotensin (NT) and neurotensin receptors (NTRs) play key roles in pancreatic ductal adenocarcinoma growth and survival (Kapuscinski et al. 1990; Mijatovic et al. 2007; Reubi et al. 1998; Wang et al. 2000a) . Using a sensitive RT-PCR procedure, NTR expression was detected in approximately 88% of resected patient tumors and in five of five patient-derived xenograft tumors (Ehlers et al. 2000) . It has been shown that primary pancreatic ductal adenocarcinomas have high NTR expression compared with normal pancreas and chronic pancreatitis samples as well as neuro endocrine tumors of the pancreas (Kapuscinski et al. 1990; Reubi et al. 1998; Wang et al. 2000a, b) . The selective and high expression of NTRs in ductal pancreatic adenocarcinomas and metastases has made them an important and promising target (Körner et al. 2015) .
Based on the selectivity of NT/NTR expression in pancreatic ductal adenocarcinomas, we hypothesize that NTR expression may be used as both a diagnostic and treatment monitoring tool.
PET imaging has a series of advantages including high sensitivity, very low concentrations of tracer molecules, unlimited depth of penetration, and quantitative properties (Beer et al. 2011; Schlyer 2004) . Previously, our group and others have reported several tracers using radiolabeled NT analog for human colon adenocarcinoma imaging (Alshoukr et al. 2011; Deng et al. 2015; Maschauer et al. 2016; Schulz et al. 2016; Wu et al. 2014 ). In contrast, fluorescent imaging is relatively low cost, safe, and easy to operate, since it does not require ionizing radiation or radioactive materials, which make it easily applicable for intraoperative tumor margin identification (Chen et al. 2008; Jennings and Long 2009; Liu et al. 2013; Seibold et al. 2014) .
There have been initial clinical studies assessing the safety and biodistribution of some NTR targeting ligands (Buchegger et al. 2003; Kulkarni et al. 2015) . However, they suffered from a small sample size and thus making it less convincing. In this study, we evaluate NTR1 expression in over a hundred human pancreatic adenocarcinomas, chronic pancreatitis, and endocrine pancreatic tumor samples by immunohistochemistry staining. Two NTR1 targeted imaging probes were then evaluated in an NTR1 positive tumor model: 64 Cu-AmBaSar-NT was used as a PET diagnostic agent and the IRDye800-NT was used as an NIR1 tracer in optical imaging and imaging guided surgery (Fig. 1 ).
Materials and methods

General
All chemicals and solvents were obtained from commercial sources and used without further purification. AmBaSar was synthesized by our research group according to literature reported procedure (Liu et al. 2012) . Lys-NT20.3 peptide (NT) was purchased from CS Bio Co. IRDye800-NHS was purchased from LI-COR Biosciences. 64 CuCl 2 was obtained from the University of Wisconsin (Madison, WI, USA). Rabbit anti-human NTR1 (ab117592), goat anti-rabbit IgG H&L (Alexa Fluor ® 488), and goat anti-rabbit IgG H&L (HRP) were purchased from Abcam.
Immunohistochemistry staining
All paraffin sections were dewaxed twice using dimethylbenzene and hydrated with anhydrous ethanol, 95, 85, 70% ethanol, and PBS in sequence. Then, the sections were immersed in 0.01 M citrate buffer (pH 6.0) and loosely covered with aluminum foil before putting in the microwave oven. The microwave power was adjusted to P100, P80, and P50, and the sections were heated for 7, 7, and 6 min, respectively. After heating, the sections were cooled at room temperature and washed with PBS for four times. 3% H 2 O 2 was used to neutralize the endogenous peroxidase. The section was blocked with goat anti-rabbit antiserum for 1 h at 37 °C. Then, the rabbit anti-human NTR1 (1:500) was added to the section and incubate at 4 °C overnight. After washing with PBS for three times, goat anti-rabbit IgG secondary antibody (1:1000) was added and incubated at 37 °C for 30 min. Then, the sections were stained with 3,3′-diaminobenzidine (DAB) and hematoxylin.
Evaluation of the immunohistochemistry results
The immunohistochemistry results were evaluated by two experienced pathologists as double-blind study. Five high visions (400×) were selected randomly to calculate the mean value based on the following methods: 0 is scored when target tissue was dyed as background color. 1 point, 2 points, and 3 points are scored when the color was yellow, yellow-brown, and brown, respectively. The number of positive cells within the field of view was also counted. 0, 1, 2, 3, and 4 points were scores when the positive cells were less than 5, 6-25, 26-50, 51-75 , and over 75%, respectively. The summation of all the results was evaluate with the below criteria: 0 points (−) negative, l-3 points (+) weakly positive, 4-5 points (++) medium positive, and 6 points or more (+++) strong positive. Integrated optical density (iOD) value of each staining slide was also measured.
Chemistry and radiochemistry
AmBaSar-NT was synthesized with our previously reported procedure (Deng et al. 2016) . For IRDye800-NT, IRdye800-NHS (200 μg, 0.17 μmol) was dissolved in 10 μL DMSO followed by adding Lys-NT20.3 (520 μg, 0.47 μmol) in 20 μL acetonitrile. 2 μL DIPEA was then added to the mixture and stayed for 2 h at room temperature in dark. The reaction mixture was purified by HPLC and the products were confirmed by MALDI-TOF: IRDye800-NT (C 98 64 Cu labeling reactions were performed according to our previously reported protocol (Deng et al. 2015) .
Cells and animals
Pancreatic adenocarcinoma cell line AsPC-1 was obtained from the Tissue Culture Facility of UNC Lineberger Comprehensive Cancer Center. The pancreatic adenocarcinoma cell lines Panc-1 and SW1990 were purchased from the Central South University's advanced cell research center. 64 Cu-AmBaSar-NT and IRDye800-NT Panc1 cells were cultured in DMEM high glucose medium; SW1990 and AsPC-1 cells were cultured in RPMI-1640 medium. All medium was added with 10% fetal bovine serum (FBS) and the cells were cultured in a humidified atmosphere of 5% CO 2 at 37 °C. When grown to 80% confluence, the cells were detached with 0.05% trypsin-EDTA for cell-binding assay or animal tumor injection. Animal procedure was performed according to a protocol approved by the UNC Institutional Animal Care and Use Committee. Male athymic nude mice of 4-6 weeks were purchased from Animal Study Facility of UNC-Chapel Hill. All work performed on animals were in accordance with and approved by UNC institutional Animal Care and Use Committee. Each mouse was subcutaneously injected with AsPC-1 pancreatic adenocarcinoma cells at a concentration of 1 × 10 6 cells per 0.1 mL in the shoulder. Animals were subjected to further imaging experiments when the tumors grew to at least 3 mm in diameter.
Cell-binding assay
The competitive cell-binding assay was used to assess the in vitro NTR1-binding affinity and specificity of NTIRDye800 and NT-AmBaSar based on the previous reported method (Alshoukr et al. 2011; Wu et al. 2014) . In brief, 50% inhibitory concentration (IC 50 ) for the binding to living HT29 cells was determined by competitive receptor binding between 125 I-labeled neurotensin (Perkin-Elmer) and nonradiolabeled NT analogs. HT29 cells (2 × 10 6 cells) were rinsed with 500 µL DMEM supplemented with 0.2% BSA and incubated for 60 min at 37 °C with 125 I-neurotensin (0.25 uCi, 300 µL DMEM, 0.2% BSA, 0.8 mM 1, 10-phenanthroline) in the presence of increasing concentrations of nonradiolabeled IRDye800-NT, AmBaSar-NT, or unmodified NT peptide. After being washed twice with ice-cold DMEM 0.2% BSA, cells were lysed in 1 mL 2 N NaOH and radioactivity was counted using 2480 WIZARD 2 gamma counter (Perkin Elmer). The data were fitted with nonlinear regression using GraphPad Prism (GraphPad Software) to calculate the 50% inhibitory concentration (IC 50 ) value. Experiments were performed in triplicate.
Reverse transcription PCR (RT-PCR) for NTR1 gene expression
The total RNA of the Panc-1 and SW1990 cell lines was extracted using RNAiso Plus reagent (TaKaRa Inc. Japan). The RNAs were then dissolved in the nuclease-free water to measure the concentration and purity with an ultramicro UV-Vis spectrophotometer. All the RNAs were reverse transcribed into cDNA under the manufacturer's instructions of PrimeScript™ RT reagent Kit with gDNA Eraser (TaKaRa Inc. Japan). The primers used for RNAs' amplification were:
5′-GGAGTGGGCTCAGAGTCTAGCAA-3′, NTR1-RP: 5′-CTCAGAAATTATGGCCCAAGGTC-3′, β-actin-FP: 5′-GCACCACACCTTCTACAATGAGC-3′, β-actin-RP: 5′-GGATAGCACAGCCTGGATAGCAAC-3′. β-Actin acted as an internal control to evaluate the relative expression of NTR1. SYBR ® Premix Ex TaqTM II kit (TaKaRa Inc. Japan) was used for fluorescent quantification.
Cell immunofluorescence
The cells were fixed with pre-cooled 4% paraformaldehyde and 0.2% Triton-X-100 was used to permeabilize the membrane for 20 min. After blocking with goat anti-rabbit serum and washing four times in PBS, the rabbit antihuman NTR1 antibody (1:400) was added to the cells and the cells were incubated in 4 °C overnight. Then, secondary antibody (1:400) was incubated with the cells in 37 °C for 50 min in dark. The cells were then washed with PBS three times before stained with 4,6-diamidino-2-phenylindole (DAPI). Photos were taken with fluorescence microscope and analyzed by the Image-Pro Plus software.
Biodistribution study and small animal PET imaging
PET scans and image analysis were performed on mouse bearing AsPC-1 xenograft. Briefly, 3.7 MBq (~100 μL) of the 64 Cu-AmBaSar-NT was injected into each animal via the tail vein (n = 3/group). At 1 and 4 h post-injection, the mice were anesthetized under 2% isoflurane in oxygen and static emission scans were acquired for 10 min using small animal PET scanner (GE eXplore Vista). The regions of interest (ROIs) were drawn over the tumor and other organs and converted to %ID/g (percentage of injected dose per gram of tissue) based on the assumption that the tissue density is 1 g/mL. Biodistribution study was performed at 4 h post-injection after PET scan. Tissues and organs of interest were harvested and weighed. Radioactivity in each sample was measured by γ counting and the radioactivity uptake was calculated as %ID/g. The mean uptake and standard deviation were calculated for each group.
In vivo NIR fluorescence imaging
Fluorescence imaging was performed using IVIS Kinetic optical imaging system (Caliper Life Sciences, Alameda, CA, USA). An ICG filter set was used for acquiring images for 10 s exposure time (f/stop = 4). Each mouse was injected 2 nmol of NT-IRDye800 intravenously and subjected to fluorescence imaging at 0.5 and 1 h post-injection. For blocking group, the probe was coinjected with 100 μg of NT20.3 peptide (n = 3/group). The mean fluorescence for each group was reported. The mouse was then subjected to optical guided surgery after 1 h post-injection imaging.
Data analysis
Quantitative data are expressed as mean ± SD except for the semi-quantification of NTR1 expression in pancreatic diseases are expressed as median value. Means were compared using one-way ANOVA and Student's t test using Graphpad Prism (GraphPad Software). P values of less than 0.05 were considered as statistically significant.
Results
Immunohistochemistry tissue staining in different pancreatic diseases
To evaluate NTR1 expression in different types of pancreatic diseases, we performed immunohistochemistry staining of NTR1 on different pancreatic diseases, including pancreatic ductal adenocarcinomas, pancreatic neuroendocrine neoplasms, and pancreatitis samples. Over one hundred patient samples are evaluated. It was found that 79.4% of the pancreatic ductal adenocarcinomas were NTR1 positive as defined by the criteria discussed above. In contrast, only 33.3% of pancreatic neuroendocrine neoplasms and 22.7% of chronic pancreatitis samples stained are positive, respectively (P < 0.001). Inpatient demographics and tumor characteristics are shown in Table 1 .
Representative immunohistochemistry images are shown in Fig. 2 : an NTR1 positive sample of pancreatic ductal adenocarcinoma (Fig. 2a) , compared to an NTR1 negative sample of an insulinoma (Fig. 2b) or a chronic pancreatitis (Fig. 2c) sample. Semi-quantification of the staining patterns is shown in Fig. 2d . The median integrated optical density (iOD) value for pancreatic ductal adenocarcinoma is 0.113, while the value for insulinoma and pancreatitis is 0.062 and 0.057, respectively. Clearly, NTR1 is a promising target for pancreatic ductal adenocarcinoma.
In vitro cell-binding affinity
The binding affinity of two NTR1 targeted probes is evaluated using cell-binding assay and the results are shown in Fig. 3a . Both IRDye800-NT and AmBaSar-NT could inhibit the binding of 125 I-NT (8-13) in a concentrationdependent manner. The IC 50 value for IRDye800-NT and AmBaSar-NT was 16.66 ± 1.31 and 9.96 ± 1.18 nM, respectively. Compared with NT20.3 (9.38 ± 0.77 nM), both imaging probes have comparable NTR1-binding affinity to the parent peptide.
NTR1 expression in pancreatic adenocarcinoma cell line and tumor models
Panc-1 and SW1990 cells were evaluated for NTR1 gene expression. We first studied the relative expression of NTR1 mRNA in these cell lines (SW1990 was used as a control). As shown in Fig. 3b , Panc-1 cell had a higher relative value of 687.83 ± 243.99 when we use the NTR1 gene expression level of SW1990 cells as a reference value. This was also confirmed by the cell immunofluorescence results shown in Fig. 3c : while both SW1990 and Panc-1 cell lines have NTR1 receptor present in cytoplasm, Panc-1 cells show a stronger fluorescence intensity compared with SW1990 cells. In addition to gene level, NTR1 expression was also evaluated in tumor tissues. Representative immunohistochemistry staining has shown strong NTR1 expression on both AsPC-1 and Fig. 3 a Cell-binding assay results of IRDye800-NT and AmBaSar-NT showed comparable binding affinity to unmodified NT peptide (n = 3/group). b Relative level of NTR1 mRNA expression in Panc-1 was significantly (P < 0.05) higher than the control SW1990 cells.
Results are normalized to SW1990 expression level. c Panc-1 cells showed stronger fluorescence intensity compared with SW1990 cells in cell immunofluorescent study Panc-1 xenograft tumor tissues (Fig. 4) , suggesting that both models are suitable for testing NTR1 targeted imaging agents.
Small animal PET imaging and biodistribution
To validate that NTR1 could serve as a PET imaging target, 64 Cu-AmBaSar-NT was prepared and evaluated in AsPC-1 xenografts (NTR1 positive). As shown in Fig. 5a , the tumor can be clearly visualized with good tumor-to-background contrast at both time points (1 and 4 h, p.i.) . High kidney uptake was observed which was decreased significantly at late time point. The tumor uptake was 3.76 ± 1.45 and 2.29 ± 0.10%ID/g at 1 and 4 h post-injection, respectively (Fig. 5b) . In addition to the small animal PET study, biodistribution studies were also performed 4 h after the injection. As shown in Fig. 5c , tumor and kidney has the highest uptake with 2.63 ± 0.55 and 2.81 ± 0.33%ID/g. Liver and intestine showed uptake with 1.10 ± 0.04 and 1.21 ± 0.032%ID/g, while other organs were essentially at Cu-AmBaSar-NT in AsPC1 tumor models at 4 h post-injection (n = 3) confirmed the tracer has high uptake in tumor and kidney background levels. The prominent tumor uptake at all time points and the high tumor-to-background contrast clearly demonstrated that NTR1 is a valid diagnosis target for PET imaging in pancreatic ductal adenocarcinoma.
Fluorescent imaging
Different from PET imaging, fluorescent imaging is relatively low cost, safe, and easy to operate, since it does not require ionizing radiation or radioactive materials. To demonstrate that NTR1 could be used in optical screening of pancreatic cancers, NT-IRDye800 was tested on AsPC-1 xenografts. Similar to PET imaging, tumors could be clearly visualized at time points examined (Fig. 6a) with high tumor-to-background ratio. The specificity of the probe was confirmed by a blocking experiment in which tracers was coinjected with an excess amount of unlabeled NT20.3. As can be seen from Fig. 6a, b , in the presence of unlabeled NT20.3, the tumor uptake (5.93 ± 0.21 × 10 8 and 4.29 ± 0.29 × 10 8 (p/s/cm 2 /sr)/(μW/cm 2 ) at 30 and 60 min post-injection, respectively) was significantly (P < 0.05) lower than that without NT (8.09 ± 0.38 × 10 8 and 6.67 ± 0.43 × 10 8 (p/s/cm 2 /sr)/(μW/cm 2 ) at 30 and 60 min post-injection, respectively).
Image-guided surgery
Another potential application of NTR1 targeted optical imaging is on intraoperative tumor identification. As a proof of principle experiment, mice with AsPC-1 xenografts were imaged by fluorescence imaging at 1 h post-injection and followed by image-guided surgery of the tumors (n = 3). In brief, the precise tumor location was identified by NIR fluorescence imaging first. Then, the tumors were resected under fluorescence guidance. These steps were repeated to ensure a complete resection of the tumor. In Fig. 6c , the feasibility for intraoperative image-guided surgical resection of the tumor nodules using NTR1 as a target is shown.
Discussion
While tumor markers are key elements in pancreatic cancer diagnosis and therapy, being able to image the size of a tumor, its location and its molecular characteristics provide a crucial diagnostic/monitoring tool that directly impacts patient management and informs possible treatment strategies. Given the urgency of these diagnostic and therapeutic needs, a great deal of interest is being devoted to cancerspecific imaging techniques that can be used for internal organs such as the pancreas.
Currently, there are several biomarkers (such as CA19-9 and CEA) being used to detect pancreatic cancers (Kruttika et al. 2012; Lamerz 1999; Naghibalhossaini et al. 2007) . The elevated serum level of these antigen and proteins showed close correlation in patients with locally advanced or metastatic unresectable pancreatic cancer (Tsavaris et al. 2009 ). Despite their clinical usefulness, these tumor markers are not effective for the early detection of small pancreatic cancer, since elevated biomarker levels in the serum indicate the presence of a significant number of cancer cells. Moreover, they failed to provide the exact location of the cancer lesions, thus making it difficult for therapy. Indeed, even after the tumor has fully been resected, the outcome in patients with early pancreatic cancer is disappointing (Hidalgo 2010) . There is clearly a need to develop new diagnostic and therapeutic methods targeting both primary and metastatic pancreatic cancer. In this study, we aim to evaluate whether NTR1 could be a valid target for pancreatic cancer imaging, and potentially therapy in the future.
NT acts through its high-affinity G-protein-coupled receptor (NTR) to regulate a variety of functions in the gastrointestinal tract, including stimulation of pancreatic and biliary secretion, colonic motility, and growth of normal intestinal mucosa and pancreas (KulinskaNiedziela and Paluszak 1997) . In addition, NTR stimulation has been shown to promote carcinogenesis and to exert a trophic effect on human colon cancer cell lines both in vitro and in vivo (Ehlers et al. 2000; Evers et al. 1992; Wang et al. 2006) . NTR mRNA expression was found in 88% of the surgical specimens examined and pancreatic ductal adenocarcinoma xenografts. In contrast, other peptide receptors which might be presented in pancreatic ductal adenocarcinoma, including VIP receptors (VIPR), substance P receptors (SPRs), and gastrin-releasing peptide (GRP) expression, were detected in only 31, 27, and 8% of pancreatic ductal adenocarcinoma examined, respectively (Ehlers et al. 2000) . In another study, enhanced expression of NTR1 mRNA was observed in pancreatic ductal adenocarcinoma; however, relatively high levels of NTR mRNA also presented in chronic pancreatitis (CP) which excludes NTR1 mRNA as a specific parameter for pancreatic ductal adenocarcinoma and for the differentiation of pancreatic ductal adenocarcinoma from CP (Wang et al. 2000a ). However, the presence of NTR1 mRNA in resected human pancreas does not necessarily correspond to the expression of the functional NTR1 in these patients. In addition, pancreatic adenocarcinoma is often comprised of a large number of nontumorous cells, including stroma and mesenchymal cells. RT-PCR performed using total tissue RNA extract may not be able to distinguish the NTR1 expression on these surrounding cells or on the tumor cells. Moreover, it is still under debate where the level of NTR1 expression correlates with tumor stage or clinical outcomes.
Instead of focusing on mRNA analysis, in our study, IHC was performed in paraffin embedded patient samples to directly assess NTR1 protein expression in pancreatic ductal adenocarcinoma, insulinoma, and CP (Table 1) . Although NTR1 mRNA expression could not differentiate pancreatic ductal adenocarcinoma from CP, NTR1 protein expression was overserved in 79.4% pancreatic ductal adenocarcinoma patients, but only 22.7% pancreatitis patients (P < 0.001). This result suggested that the detection of NTR1 expression at protein level may be used to facilitate the differential diagnosis of pancreatic ductal adenocarcinoma from CP, which also justified the importance of showed clear tumor contrast in positive group and the tracer specificity was confirmed by blocking group (n = 3/group). b The quantitative tumor uptakes derived from fluorescent imaging was significantly (P < 0.05) different at both time points in positive and blocking group. c Mouse bearing AsPC1 tumor at 1 h post-injection of NTIRDye800. The tumor lesion could be successfully removed by fluorescent imaging guided surgery. Upper row is digital pictures during the surgery and lower row is fluorescent images development of NTR1 targeting imaging probes for diagnostic imaging. However, no association was observed between NTR1 expression level and pathological grading of pancreatic ductal adenocarcinoma (P = 0.064), which indicated that NTR1 imaging may have limited application for cancer staging. We do like to point out that the NTR1 expression level analysis is only semi-quantification, which need to be improved in the future. Nonetheless, it was clearly demonstrated NTR1 is a promising target for pancreatic cancer research.
With the encouraging histology data on hand, we then confirmed that both Panc-1 and AsPC1 are NTR1 positive (this is also confirmed by the previous literature report) (Na et al. 2015; Olszewski and Hamilton 2009) . We would like to point out that we also observed cytoplasmic localization of NTR1 based on cell staining results (Fig. 3) , which should mainly present on the plasma membrane. Previously, it has been reported that both prostate cancer and Ewing's sarcoma cells might have NT/NTR1 autocrine loop pathway to promote cell proliferation and leads to NTR1 internalization after forming complex with NT peptide (Reubi et al. 1999; Sehgal et al. 1994; Valerie et al. 2011) . Therefore, the observed cytoplasmic signal in pancreatic ductal adenocarcinoma cells here could possibly be caused by the internalization of NTR1 in the presence of NT. Further experiments will be needed to confirm this hypothesis. AsPC1 tumor model was used thereafter to study NTR1 targeted PET and fluorescent imaging agents. As mentioned above, PET imaging has advantage in detecting metastasis, recurrence, and monitoring response to therapy noninvasively. The encouraging PET imaging results in Fig. 5 clearly demonstrated the feasibility of targeting NTR1 for pancreatic ductal adenocarcinoma imaging. Despite the encouraging imaging result on NTR1 targeted PET agent, this approach will not be feasible for patient screening due to the overall low incident rate of pancreatic ductal adenocarcinoma, radiation exposure, and high cost. Therefore, fluorescence imaging was then proposed to be used for potential screening and image-guided surgery. Optical imaging has similar picomolar or nanomolar sensitivity compared to PET but does not require ionizing radiation, which enables repeated imaging without radiation risks. Moreover, optical imaging is relatively cheap and imaging agents are easier to generate than PET tracers. As for the depth penetration issue in optical imaging, using NIR light and advanced more sensitive detection equipment, penetration depth in human tissue is now possible up to 15 cm (Herranz and Ruibal 2012) . The result in Fig. 6 showed that NTR1 can successfully locate the pancreatic ductal adenocarcinoma tumor in optical imaging and may facilitate imaging guided surgery. This further proved our hypothesis that NTR1 targeted fluorescence imaging can be used for potential screening.
Conclusion
To evaluate the potential of using NTR1 as a target for imaging and therapy in pancreatic ductal adenocarcinoma, immunohistochemistry staining of NTR1 was performed on patient tissue samples, which demonstrated the high incident rate of NTR1 expression in pancreatic ductal adenocarcinoma. With this encouraging data in hand, we tested both PET and fluorescent NTR1 targeting probes in AsPC1 tumor model (NTR1 positive). Both agents provided prominent tumor uptake and good tumor-to-background contrast. The imaging probes reported here could potentially not only be used for precise diagnosis of pancreatic ductal adenocarcinoma, but also be fully integrated into patient screening (using optical probe) and treatment monitoring of NTR1 targeted therapy.
